{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-083961","form_type":"8-K","ticker":"INMB","cik":"0001711754","company_name":"Inmune Bio, Inc.","filed_at":"2026-07-31T20:06:04+00:00","discovered_at":"2026-07-31T20:07:00.623843+00:00","generated_at":"2026-07-31T20:07:22.168149+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INmune Bio receives ~$4.6M in R&D rebates from Australia and UK, extends cash runway","bullets":["Received ~$4.2M R&D cash rebate from Australia on July 30, 2026, plus ~$0.4M from UK in June 2026.","Combined ~$4.6M in non-dilutive rebates exceeded net cash used in Q2 operating activities (after adjusting for UK rebate).","Strengthens balance sheet and extends cash runway without issuing additional equity.","Rebates support advancement of CORDStrom toward regulatory filings (MAA UK MHRA 2026, EU EMA 2027, US BLA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-083961","json":"https://secwatch.observer/filing/0001213900-26-083961.json","markdown":"https://secwatch.observer/filing/0001213900-26-083961.md","text":"https://secwatch.observer/filing/0001213900-26-083961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/0001213900-26-083961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711754/000121390026083961/ea0300069-8k_inmune.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T20:07:22.168149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}